New Molecular Target for Cancer Treatment

Share

broccoliThe anti-cancer properties of members of the Brassica family have been recognized since the 1970s and one component, indole-3-carbinol, is already undergoing clinical trials. Indole-3-carbinol induces a G1 cell-cycle arrest of human breast cancer cells, but the underlying molecular mechanisms were not understood. A group at the University of California has now shown that indole-3-carbinol prevents proteolytic processing of the 50-kDa form of cyclin E to a 35-kDa form by neutrophil elastase. The 50-kDa form is typically expressed in normal mammary tissue whereas the 35 kDa form is linked with cancer progression and poor clinical outcomes. Using either cyclin E or the synthetic substrate, N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide, the group were able to demonstrate that indole-3-carbinol inhibits neutrophil elastase with an inhibitory constant of ca 12µM. Neutrophil elastase is the first specific target to be identified for the anti-cancer properties of indole-3-carbinol. The study points to the use of elastase inhibitors for the treatment of cancers where high levels of proteolytic activity are associated with a poor prognosis. The group has already identified compounds that are greater than 100-fold more active in cell culture experiments and hopes that these will play an important role in combination with other cancer therapies. The study is published in the journal PNAS.


Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>